middle.news
How Patrys’ Injectable Quetiapine Could Transform the $2B Delirium Market
8:32am on Tuesday 31st of March, 2026 AEDT
•
Healthcare
Read Story
How Patrys’ Injectable Quetiapine Could Transform the $2B Delirium Market
8:32am on Tuesday 31st of March, 2026 AEDT
Key Points
Injectable quetiapine reformulation targets ICU delirium market valued over US$2 billion
Accelerated FDA 505(b)(2) regulatory pathway with 3–5 year development timeline
Development costs estimated at $20–30 million, significantly lower than new drug discovery
Patent protection secured until approximately 2042 for proprietary formulation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PATRYS (ASX:PAB)
OPEN ARTICLE